Menopausal hormone therapy linked to stronger bone density, study finds
Women undergoing menopausal hormone therapy (MHT) face a decreased risk of developing low bone mineral density compared to those who do not use such therapy, according to a new study. The findings are set to be presented this Sunday at ENDO 2026, the Endocrine Society's annual meeting in Chicago.
The research highlights the potential protective role of hormone replacement in maintaining skeletal integrity during the menopausal transition. As women age and approach menopause, the natural decline in estrogen levels can lead to a significant reduction in bone mineral density, increasing the vulnerability to osteoporosis and related fractures. Maintaining bone health is a critical aspect of long-term wellness for aging women.
By providing a comparative analysis between users and non-users of hormonal therapies, the study underscores how medical intervention can help mitigate the long-term skeletal impacts of hormonal shifts. These results are expected to contribute to the ongoing clinical discussions regarding the management of menopause and bone health preservation.
The Endocrine Society’s annual meeting, ENDO, serves as a global platform for researchers and clinicians to present groundbreaking developments in endocrinology. The upcoming presentation in Chicago will offer healthcare professionals deeper insights into how menopausal hormone therapy can be integrated into holistic bone health strategies for women, potentially influencing future clinical guidelines for menopause management.
